Cargando…

Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial

PURPOSE: To develop a population pharmacokinetic (PK) model for intravitreal ranibizumab in infants with retinopathy of prematurity (ROP) and assess plasma free vascular endothelial growth factor (VEGF) pharmacodynamics (PD). METHODS: The RAnibizumab compared with laser therapy for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fidler, Matthew, Fleck, Brian W., Stahl, Andreas, Marlow, Neil, Chastain, James E., Li, Jun, Lepore, Domenico, Reynolds, James D., Chiang, Michael F., Fielder, Alistair R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Association for Research in Vision and Ophthalmology 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422765/ https://www.ncbi.nlm.nih.gov/pubmed/32855889 http://dx.doi.org/10.1167/tvst.9.8.43

Ejemplares similares

Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010
por: Blencowe, Hannah, et al.
Publicado: (2013)

Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016)

Effect of ranibizumab on retinopathy of prematurity: A meta-analysis
por: Wang, Zhibin, et al.
Publicado: (2022)

Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity
por: Patel, Samir N, et al.
Publicado: (2019)

Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity
por: Chandra, Parijat, et al.
Publicado: (2019)

Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity
por: Prajapati, Vipul, et al.
Publicado: (2023)

Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis
por: Alva, Niza, et al.
Publicado: (2023)

Associations of VEGF Polymorphisms With Retinopathy of Prematurity
por: Ling, Xiao Chun, et al.
Publicado: (2023)

Incidence and risk factors of retinopathy of prematurity in an Italian cohort of preterm infants
por: Dani, Carlo, et al.
Publicado: (2021)

Combination of Intravitreal Ranibizumab and Laser Photocoagulation for Aggressive Posterior Retinopathy of Prematurity
por: Mota, Ágata, et al.
Publicado: (2012)

Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy
por: Chan, Joyce J. T., et al.
Publicado: (2016)

Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment
por: Gotz-Więckowska, Anna, et al.
Publicado: (2017)

Intravitreal ranibizumab for retinopathy of prematurity: The ocular and systemic safety profile query
por: Al Kalbani, Khulood, et al.
Publicado: (2023)

Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity
por: Arámbulo, Odalis, et al.
Publicado: (2015)

Combination therapy of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity
por: Dudani, Ajay I, et al.
Publicado: (2022)

Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity
por: Hartnett, M. Elizabeth, et al.
Publicado: (2023)

Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
por: Huang, Qiujing, et al.
Publicado: (2017)

Systemic biomarkers of retinopathy of prematurity in preterm babies
por: Sehgal, Parrina, et al.
Publicado: (2022)

Potential for a paradigm change in the detection of retinopathy of prematurity requiring treatment
por: Gilbert, Clare, et al.
Publicado: (2016)

Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
por: Menke, Marcel N, et al.
Publicado: (2015)

Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage
por: Xu, Yu, et al.
Publicado: (2016)

Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab
por: Tong, Qizhe, et al.
Publicado: (2018)

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity
por: Gangwe, Anil Babanrao, et al.
Publicado: (2021)

Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity
por: Hoppe, Charis, et al.
Publicado: (2022)

Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity
por: McLeod, D Scott, et al.
Publicado: (2016)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

Intravitreal ranibizumab as salvage therapy in an extremely low–birth-weight infant with rush type retinopathy of prematurity
por: Lin, Chun-Ju, et al.
Publicado: (2012)

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
por: Lin, Chun-Ju, et al.
Publicado: (2016)

Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study
por: Hu, Qinrui, et al.
Publicado: (2017)

COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY
por: Zhang, Guoming, et al.
Publicado: (2017)

Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity
por: Chen, Xuting, et al.
Publicado: (2019)

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity
por: Jin, Enzhong, et al.
Publicado: (2019)

Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity
por: Cao, Jing-Ke, et al.
Publicado: (2023)

Use of intravitreal anti-VEGF: Retinopathy of prematurity surgeons’ in Hamlet's dilemma?
por: Azad, Rajvardhan
Publicado: (2011)

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
por: Papadopoulos, Nicholas, et al.
Publicado: (2012)

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept
por: Ichiyama, Yusuke, et al.
Publicado: (2022)

Risk Factors for Retinopathy of Prematurity in Extremely Preterm Chinese Infants
por: Yau, Gordon S.K., et al.
Publicado: (2014)

Blood protein profiles related to preterm birth and retinopathy of prematurity
por: Danielsson, Hanna, et al.
Publicado: (2021)

Clinical Characteristics of Preterm Neonates with Aggressive Posterior Retinopathy of Prematurity
por: Abdel Salam Gomaa, Nancy, et al.
Publicado: (2021)

Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity
por: Zhao, Jinfeng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hj2v3hq0jr23u5ne73fhqvgvci